Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2389-2398

  Wang, Xiaofu ^c   Jackson, Lindsey N ^c   Johnson, Sara M ^c   Wang, Qingding ^a,b   Evers, B Mark ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; BUTYRIC ACID; CYCLOOXYGENASE 2; ENTINOSTAT; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BUTYRATES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DOWN-REGULATION; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; NEUROTENSIN; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, NEUROTENSIN;

EID: 77955498516     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1080     Document Type: Article

References (50)

1. Ferris CF, Carraway RE, Hammer RA, Leeman SE. Release and degradation of neurotensin during perfusion of rat small intestine with lipid. Regul Pept 1985;12:101-11.
2. Chung DH, Evers BM, Shimoda I, Townsend CM, Jr., Rajaraman S, Thompson JC. Effect of neurotensin on gutmucosal growth in rats with jejunal and ileal Thiry-Vella fistulas.Gastroenterology 1992;103:1254-9.
3. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides 2006;27:2424-33.
4. Evers BM, Izukura M, Townsend CM, Jr., Uchida T, Thompson JC. Differential effects of gut hormones on pancreatic and intestinal growth during administration of an elemental diet. Ann Surg 1990; 211:630-6, discussion 6-8.
5. Dupouy S, Viardot-Foucault V, Alifano M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One 2009;4:e4223.
6. Iwase K, Evers BM, Hellmich MR, et al. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997;79:1787-93. (Pubitemid 27176362)
7. Thomas RP, Hellmich MR, Townsend CM, Jr., Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003;24:571-99.
8. Wang X, Wang Q, Ives KL, Evers BM. Curcumin inhibits neurotensinmediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 2006;12:5346-55.
9. Yoshinaga K, Evers BM, Izukura M, et al. Neurotensin stimulates growth of colon cancer. Surg Oncol 1992;1:127-34.
10. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999;80:448-54.
11. Najimi M, Maloteaux JM, Hermans E. Cytoskeleton-related trafficking of the EAAC1 glutamate transporter after activation of the G (q/11)-coupled neurotensin receptor NTS1. FEBS Lett 2002;523: 224-8.
12. Chao C, Tallman ML, Ives KL, Townsend CM, Jr., Hellmich MR. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005;129:313-21.
13. Maoret JJ, Pospai D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 1994;203:465-71. (Pubitemid 24281117)
14. Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 2000;269:704-8.
15. Hassan S, Dobner PR, Carraway RE. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul Pept 2004;120:155-66.
16. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3:28-37.
17. Glauben R, Sonnenberg E, Zeitz M, Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009; 280:154-9.
18. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
19. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
20. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 2006;25:3885-93.
21. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14:R546-51.
22. Kim YS, Tsao D, Siddiqui B, et al. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer 1980;45:1185-92. (Pubitemid 10125129)
23. Wang Q, Zhou Y, Wang X, Chung DH, Evers BM. Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-êB inhibition. Cancer Res 2007;67: 7773-81.
24. Wang Q, Zhou Y, Wang X, Evers BM. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 2006;25:43-50.
25. Ding Q, Wang Q, Evers BM. Alterations of MAPK activities associated with intestinal cell differentiation. Biochem Biophys Res Commun 2001;284:282-8. (Pubitemid 32917972)
26. Wang Q, Zhou Y, Wang X, Evers BM. p27 Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. Cell Death Differ 2008;15:908-19.
27. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-êB. J Biol Chem 2003;278: 51091-9.
28. Evans PM, Zhang W, Chen X, Yang J, Bhakat KK, Liu C. Kruppel- like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. J Biol Chem 2007; 282:33994-4002.
29. Wang Q, Ji Y, Wang X, Evers BM. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 2000;276:466-71.
30. R1. SAS Institute Inc., SAS/STAT® 9.1 User's Guide Volumes 1 and 2. Cary, NC: SAS Institute Inc.; 2004.
31. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998;95:6791-6. (Pubitemid 128620041)
32. Souaze F, Viardot-Foucault V, Roullet N, et al. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 2006;27:708-16.
33. Brun P, Mastrotto C, Beggiao E, et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G621-9.
34. Chavey C, Muhlbauer M, Bossard C, et al. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-κB pathway in breast cancer. Mol Pharmacol 2008;74:1359-66.
35. Kim YK, Lee EK, Kang JK, et al. Activation of NF-êB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ 2006;13: 2033-41.
36. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007;17:363-9.
37. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A 1994;91:4673-7.
38. Rivera CA, Ahlberg NC, Taglia L, Kumar M, Blunier A, Benya RV. Expression of GRP and its receptor is associated with improved survival in patients with colon cancer. Clin Exp Metastasis 2009; 26:663-71.
39. Kim YK, Seo DW, Kang DW, Lee HY, Han JW, Kim SN. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem Biophys Res Commun 2006;347:1088-93.
40. Schauber J, Iffland K, Frisch S, et al. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol 2004;41:847-54. (Pubitemid 38903168)
41. Tatebe H, Shimizu M, Shirakami Y, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009;285:210-7.
42. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-86.
43. Cui H, Meng Y, Bulleit RF. Inhibition of glycogen synthase kinase 3beta activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res 1998;111:177-88.
44. Korswagen HC, Coudreuse DY, Betist MC, van de Water S, Zivkovic D, Clevers HC. The Axin-like protein PRY-1 is a negative regulator of a canonical Wnt pathway in C. elegans. Genes Dev 2002;16: 1291-302. (Pubitemid 34553109)
45. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9.
46. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002;22:2099-110.
47. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des 2003;9: 2177-90.
48. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98.
49. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000;12:78-85. (Pubitemid 30042685)
50. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76. (Pubitemid 37328911)